Paris - Delayed Quote EUR

OSE Immunotherapeutics SA (OSE.PA)

5.43

+0.07

+(1.31%)

At close: April 11 at 5:35:28 PM GMT+2

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – April 9, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that the Company will present f

GlobeNewswire 4 days ago

OSE.PA
+1.31%
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking1 cytokine bispecific technology.CLEC-1, a novel immune checkpoint target. NANTES, France – April 3, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that the latest preclinical data on its novel OSE-CYTOMAS

GlobeNewswire 10 days ago

OSE.PA
+1.31%
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial visibility until Q1 2027 Three strategic agreements signed: licensing and collaboration with AbbVie (worth up to $713 million), and anti-SIRPα program expansions (worth up to €1.1 billion), plus a purchase asset agreement with Boehringer Ingelheim. €8.4 million in non-dilutive public funding as part o

GlobeNewswire 18 days ago

OSE.PA
+1.31%
OSE announces overall survival success in Phase II PDAC vaccine trial

The Phase II trial examined the therapeutic cancer vaccine Tedopi in combination with chemotherapy drug combination FOLFIRI.

Clinical Trials Arena last month

GLDAF

OSE.PA
+1.31%
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer Primary endpoint met in randomized Phase 2 trial evaluating OSE2101 (Tedopi®) with FOLFIRI in Advanced Pancreatic CancerDetailed results to be presented at upcoming medical congresses NANTES, France – March 11, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and the GERCOR Group today announced that the primary en

GlobeNewswire last month

OSE.PA
+1.31%
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD NANTES, France – March 6, 2025, 6:00pm CET - OSE Immunotherapeutics recently hosted a webinar featuring key opinion leaders (KOLs) to discuss the latest clinical trial results and scientific data on Lusvertikimab, particularly its positive outcomes in treating ulcerative colitis (UC). The webinar included insights from: Prof Laurent Peyrin-Biroulet, Professor of Gastroenterology, Nancy University Hospital,

GlobeNewswire last month

OSE.PA
+1.31%
OSE’s UC therapy prompts 16% clinical remission after ten weeks

The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.

Clinical Trials Arena last month

OSE.PA
+1.31%
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO Lusvertikimab achieved statistical significance on the primary and secondary endpoints in moderate to severe active ulcerative colitis (UC) patients during the 10-week induction period of treatment in the randomized, double-blind CoTikiS Phase 2 study. These results were presented in the Top 10 congress highlights oral plenary session at ECCO 2025.Lusv

GlobeNewswire last month

OSE.PA
+1.31%
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic ColitisIn Oral Presentation at 20th Congress of ECCO NANTES, France – February 20, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today presented positive preclinical data on the combination of anti-IL-7 receptor (IL-7R) with anti-IL-12/23 monoclonal antibody (mAb) in chronic colitis at the 20th Congress of ECCO (European Crohn’s and Colitis Orga

GlobeNewswire last month

OSE.PA
+1.31%
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris - France, January 29, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Scienta Lab, a leader in Artificial Intelligence (AI)-driven precision immunology, announce a strategic collaboration to harness Scienta Lab’s advanced AI platform for modeling inflammatory diseases and identifying predictive biomarkers of effi

GlobeNewswire 2 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO NANTES, France - January 28 2025, – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), shares details of the three scientific abstracts on its anti-IL-Receptor (IL-7R) Lusvertikimab, which is in clinical development for ulcerative colitis. These abstracts will be presented in Oral Presentation, Digital Oral Presentation and Poster Presentation

GlobeNewswire 2 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Dr. Sonya Montgomery as Chief Development Officer. Sonya will serve on the OSE Immunotherapeutics Executive Committee in a strategic move that will enhance the company’s development capabilities. Dr. Montgomery brings over two decades of experience leading R&D strategies at

GlobeNewswire 2 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral abstracts for 20th Congress of European Crohn’s and Colitis Organization (ECCO) Highlights. Research highlights OSE Immunotherapeutics’ continued commitment to advancing the treatment and management of IBD. NANTES, France, December 18, 2024 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127

GlobeNewswire 3 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol approved globally. Most countries and sites activated, with full activation expected in H1 2025. First patients enrolled in this international Phase 3 registration study of Tedopi® in monotherapy in second-line Non-Small Cell Lung Cancer (NSCLC).TEDOVA: Completion of patient enrollment in the Phase 2 study of Tedopi® alone or in combination with Keytruda®

GlobeNewswire 3 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Strengthens Leadership and Executive Committee

OSE Immunotherapeutics Strengthens Leadership and Executive Committee NANTES, France, December 2, 2024 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that it has strengthened the company’s leadership and executive team with two new appointments. Fiona Olivier has been appointed Chief Corporate Affairs and Investor Relations Officer and has joined the Executive Committee of OSE Immunotherapeutics. Aurore Morello, Head of Research and Director of R&D Pro

GlobeNewswire 4 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis Lusvertikimab met the primary endpoint (modified Mayo Score improvement) at each dose tested during the 10 week-induction period of treatment in the randomized double-blind CoTikiS Phase 2 study. Highly favorable positive results on the key secondary endpoints demonstrating significantly high rate of clinical an

GlobeNewswire 5 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral presentations selected for international conferences: The Festival of Biologics in Basel, Switzerland (October 17, 2024)The 16th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Barcelona, Spain (November 7, 2024)The Antibody Therapeutics Xchange in Brussels (November 18, 20

GlobeNewswire 5 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new partnerships.New strategic partnership with AbbVie for up to $713 million, including $48 million received upon signature.Major partnership expansion with Boehringer Ingelheim: Amendment of the collaboration and licensing agreement on first-in-class SIRPα compounds developed both in immuno-oncology and now expected

GlobeNewswire 6 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer Trial begins in the United States, Canada, Europe and United Kingdom after successful regulatory authorizations in 14 countries.Trial in Progress presentation at the 2024 World Conference on Lung Cancer in San Diego and at the European Society for Medical Oncology congress 2024 in Barcelona. Nantes, France – September 10, 2024 – 7:30 am CET – O

GlobeNewswire 6 months ago

OSE.PA
+1.31%
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab demonstrates significant efficacy during the 10 week-induction phase of treatment, in the randomized double-blind CotiKis phase 2 study Favorable safety and tolerability profile in the whole patient population across the two doses tested and during the open label phase of treatment First anti-IL7R mAb positive efficacy study enabling pathway of f

GlobeNewswire 8 months ago

OSE.PA
+1.31%

Performance Overview

Return	OSE.PA	CAC 40 (^FCHI)
YTD	-24.27%	-3.74%
1-Year	+15.53%	-11.45%
3-Year	-34.26%	+8.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

OSE Immunotherapeutics SA (OSE.PA)

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

OSE announces overall survival success in Phase II PDAC vaccine trial

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE’s UC therapy prompts 16% clinical remission after ten weeks

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Strengthens Leadership and Executive Committee

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

Performance Overview